FPMI Zgłoszenia SEC - FluoroPharma Medical, Inc.- Raport roczny, oświadczenie o pełnomocnictwie, Prospekt

Podstawowe statystyki

CIK

1402785

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to FluoroPharma Medical, Inc.

SEC Filings (Chronological Order)

Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.

October 13, 2022	15-15D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 333-147193 FluoroPharma Medical Inc. (Exact name of registrant as speciﬁed
June 23, 2022	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 22, 2022 (Date of earliest event reported: June 22, 2022) FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State of incorporation) 333-151381 (Commission File No.) 20-8325
June 23, 2022	EX-99.1	99.1 Order Granting Appointment of Custodian pursuant to NRS78.347 (Case No. A-22-850894-P) issued by the District Court of the State of Nevada in and for Clark County. Exhibit 99.1
May 15, 2017	NT 10-Q	FluoroPharma Medical 0-Q FluoroPharma Medical, Inc. - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-147193 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ]
March 31, 2017	10-K	FPMI / FluoroPharma Medical, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) FluoroPharma Medical, Inc. (Exact name of
March 20, 2017	CT ORDER	FluoroPharma Medical RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 20, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 FluoroPharma Medical, Inc.
March 15, 2017	EX-4.5	EX-4.5 SEC Connect Exhibit 4.5
March 15, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 24, 2017 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325
March 15, 2017	EX-10.4	SECURITY AGREEMENT SEC Connect Exhibit 10.4 SECURITY AGREEMENT THIS SECURITY AGREEMENT is entered into as of February , 2016 (the “Security Agreement”), by and between the undersigned creditors (“Creditors”), and FLUOROPHARMA MEDICAL, INC., a Nevada corporation, located at 8 Hillside Avenue, Suite 108, Montclair, NJ 07042 (the “Borrower”). RECITALS A. Creditors have agreed to extend to Borrower a loan or loans in th
March 15, 2017	EX-10.5	INTERCREDITOR AGREEMENT SEC Connect Exhibit 10.5 INTERCREDITOR AGREEMENT THIS INTERCREDITOR AGREEMENT (the ?Agreement?) is dated as of February , 2017, and is between ?Agents? , with an address of , , and , with an address of , , and ?Participant? or ?Participants? on Schedule I attached hereto, with their address set forth opposite their names. In this Agreement, the following terms shall have the following respective m
March 15, 2017	EX-10.3	REGISTRATION RIGHTS AGREEMENT Blueprint Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement, dated as of February , 2017, is by and among FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?), and those investors set forth on Schedule A to this Agreement (the ?Investors?). The Company and the Investors may be collectively referred to as the ?Parties.? RECITALS The Investors have agreed to e
March 15, 2017	EX-10.1	NOTE PURCHASE AGREEMENT SEC Connect Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this ?Agreement?), is dated as of February , 2017, by and between FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?), and the Purchasers identified on Schedule 1 hereto (the ?Purchasers?). WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon an exemption from
March 15, 2017	EX-4.1	SENIOR SECURED CONVERTIBLE PROMISSORY NOTE SEC Connect Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJ
March 15, 2017	EX-4.4	AMENDMENT NO. 5 TO PROMISSORY NOTE FLUOROPHARMA MEDICAL, INC. SEC Connect Exhibit 4.4 AMENDMENT NO. 5 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. THIS AMENDMENT NO. 5 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this ?Amendment?), dated as of January 22, 2017, is made by FluoroPharma Medical, Inc., a Nevada corporation (the ?Company? or the ?Borrower?), and the undersigned holders (each, a ?Holder? and, collectively, the ?Holders?). The Company and
March 2, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2017 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-832
March 2, 2017	EX-10.1	[Signature page follows] SEC Connect Exhibit 10.1 WAIVER This waiver (this ?Waiver?) is granted as of February [21], 2017, by Platinum-Montaur Life Sciences, LLC, a Delaware limited liability company (?Platinum Montaur?) in favor of FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?). Capitalized terms used but not defined herein shall have the meaning given to such term in the Purchase Agreement and the Warr
December 29, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-83256
December 29, 2016	EX-4.1	FLUOROPHARMA MEDICAL, INC. PROMISSORY NOTE Blueprint Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER
December 15, 2016	10-Q/A	FluoroPharma Medical FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2016 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exa
December 5, 2016	EX-4.2	AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE FLUOROPHARMA MEDICAL, INC. SEC Connect Exhibit 4.2 AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. THIS AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this ?Amendment?), dated as of November , 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the ?Company? or the ?Borrower?), and the undersigned holders (each, a ?Holder? and, collectively, the ?Hol
December 5, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 29, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-832
November 14, 2016	10-Q	FluoroPharma Medical FORM 10-Q (Quarterly Report) 10-Q 1 fpmi10qsep302016.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2016 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 3
November 4, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commiss
September 30, 2016	EX-4.1	FLUOROPHARMA MEDICAL, INC. PROMISSORY NOTE Blueprint Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER
September 30, 2016	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 27, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-83
August 18, 2016	EX-3.1	EX-3.1 ex3-1.htm Exhibit 3.1
August 18, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders fpmi8kaug152016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381
August 18, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders fpmi8kaug152016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381
August 18, 2016	EX-3.1	EX-3.1 ex3-1.htm Exhibit 3.1
August 15, 2016	10-Q	FluoroPharma Medical FORM 10-Q (Quarterly Report) fpmi10qjune302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2016 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharm
August 15, 2016	EX-10.1	The General Hospital Corporation AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220395.01 MGH Case Number: 02390 EX-10.1 2 ex10-1.htm AMENDMENT TO LICENSE AGREEMENT Exhibit 10.1 The General Hospital Corporation AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220395.01 MGH Case Number: 02390 THIS Amendment to the license agreement (the “Amendment”) is effective as of June 1, 2016 (“Amendment Effective Date”), by and between The General Hospital Corporation d/b/a Massachusetts General Hospital, a Not-For-Pro
August 15, 2016	EX-10.2	The General Hospital Corporation AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220396.01 MGH Case Number: 02155 EX-10.2 3 ex10-2.htm AMENDMENT TO LICENSE AGREEMENT Exhibit 10.2 The General Hospital Corporation AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220396.01 MGH Case Number: 02155 THIS Amendment to the license agreement (the “Amendment”) is effective as of June 1, 2016 (“Amendment Effective Date”), by and between The General Hospital Corporation d/b/a Massachusetts General Hospital, a Not-For-Pro
August 15, 2016	10-Q	FluoroPharma Medical FORM 10-Q (Quarterly Report) fpmi10qjune302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2016 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharm
August 15, 2016	EX-10.2	The General Hospital Corporation AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220396.01 MGH Case Number: 02155 EX-10.2 3 ex10-2.htm AMENDMENT TO LICENSE AGREEMENT Exhibit 10.2 The General Hospital Corporation AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220396.01 MGH Case Number: 02155 THIS Amendment to the license agreement (the “Amendment”) is effective as of June 1, 2016 (“Amendment Effective Date”), by and between The General Hospital Corporation d/b/a Massachusetts General Hospital, a Not-For-Pro
July 27, 2016	EX-10.3	AMENDMENT NO. 1 TO NOTE PURCHASE AGREEMENT ex10-3.htm Exhibit 10.3 AMENDMENT NO. 1 TO NOTE PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO NOTE PURCHASE AGREEMENT by and between FLUOROPHARMA MEDICAL, INC. and one or more Purchasers (this “Amendment”), dated initially as of July 22, 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the undersigned (each, a “Purchaser” and, collectively, the “Purchasers”). The
July 27, 2016	EX-4.2	AMENDMENT NO. 3 TO PROMISSORY NOTE FLUOROPHARMA MEDICAL, INC. ex4-2.htm Exhibit 4.2 AMENDMENT NO. 3 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. THIS AMENDMENT NO. 3 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this ?Amendment?), dated as of July 22, 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the ?Company? or the ?Borrower?), and the undersigned holders (each, a ?Holder? and, collectively, the ?Holders?). The Company and the
July 27, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits fpmi8kjuly222016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 22, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 2
July 27, 2016	CT ORDER	FluoroPharma Medical RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION 27 July 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 FluoroPharma Medical, Inc.
July 20, 2016	DEF 14A	FluoroPharma Medical DEFINITIVE SCHEDULE 14A fpmidef14ajuly2016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule
July 18, 2016	EX-99.1	EX-99.1 ex99-1.htm Exhibit 99.1
July 18, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits fpmi8kjuly182016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 18, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 2
July 1, 2016	PRE 14A	FluoroPharma Medical PRELIMINARY SCHEDULE 14A PRE 14A 1 fpmipre14ajuly2016.htm PRELIMINARY SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Co
June 9, 2016	EX-99.1	-1- ex99-1.htm Exhibit 99.1 FluoroPharma Enters Development and Commercialization Agreement for China and Canada Montclair, NJ - (Marketwired) - June 6, 2016 - FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agree
June 9, 2016	EX-10.1	CONFIDENTIAL TREATMENT REQUESTED. ex10-1.htm CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[*******]? OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. Exhibit 10.1 EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT This Exclusive Licensing and Distribution Agreement (?A
June 9, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits fpmi8kjun32016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2016 FLUOROPHARMA MEDICAL, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction of Incorporatio
June 9, 2016	EX-10.2	CONFIDENTIAL TREATMENT REQUESTED. ex10-2.htm CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[*******]? OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. Exhibit 10.2 EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT This Exclusive Licensing and Distribution Agreement (?A
May 31, 2016	EX-4.2	AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE FLUOROPHARMA MEDICAL, INC. ex4-2.htm EXHIBIT 4.2 AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. THIS AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this ?Amendment?), dated as of May 26, 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the ?Company? or the ?Borrower?), and the undersigned holders (each, a ?Holder? and, collectively, the ?Holders?
May 31, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant fpmi8kmay242016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2016 FLUOROPHARMA MEDICAL, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction of Incorporati
May 16, 2016	10-Q	FluoroPharma Medical FORM 10-Q (Quarterly Report) fpmi10qmar312016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2016 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharm
May 4, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant fpmi8kapr262016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 2
March 30, 2016	10-K	FluoroPharma Medical FORM 10-K (Annual Report) 10-K 1 fpmi10kdec312015.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) Fluo
March 23, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant fpmi8kmar232016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 23, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 2
March 23, 2016	EX-10.2	REGISTRATION RIGHTS AGREEMENT ex10-2.htm Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of March , 2016, by and among FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?), and the purchasers signatory hereto (each, a ?Purchaser? and collectively, the ?Purchasers?). This Agreement is made pursuant to the Note Purchase Agreement, dated as o
March 23, 2016	EX-4.1	Principal Amount: $_____ Issue Date: March __, 2016 ex4-1.htm Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJEC
March 23, 2016	EX-10.1	NOTE PURCHASE AGREEMENT ex10-1.htm Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is dated as of March , 2016, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the Purchasers identified on Schedule 1 hereto (the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon an exemption from sec
February 8, 2016	424B3	FLUOROPHARMA MEDICAL, INC. 23,820,973 shares of Common Stock fpmi424b3feb2016.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-208196 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 23,820,973 shares of Common Stock This prospectus relates to the resale, from time to time, of up to 23,820,973 shares of our common stock, par value $.001 per share, being offered by the selling stockholders identified in this prospectus. The shares of common stock offered under
February 5, 2016	CORRESP	FluoroPharma Medical ESP February 5, 2016 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: FluoroPharma Medical, Inc Pre-Effective Amendment No. 3 to Registration Statement on Form S-1 (the ?Registration Statement?) File No. 333-208196 Ladies and Gentlemen: FluoroPharma Medical, Inc. (the ?Company?) hereby requests that the effective date of the above-captioned Registration Statement be
February 4, 2016	S-1/A	As filed with the Securities and Exchange Commission on February 4 , 2016 As filed with the Securities and Exchange Commission on February 4 , 2016 Registration No.
January 28, 2016	S-1/A	As filed with the Securities and Exchange Commission on January 28 , 2016 As filed with the Securities and Exchange Commission on January 28 , 2016 Registration No.
January 26, 2016	S-1/A	As filed with the Securities and Exchange Commission on January 26, 2016 As filed with the Securities and Exchange Commission on January 26, 2016 Registration No.
January 25, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits fpmi8kjan202016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 20, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381
January 25, 2016	EX-4.2	AMENDMENT NO. 2 TO PROMISSORY NOTE FLUOROPHARMA MEDICAL, INC. ex4-2.htm Exhibit 4.2 AMENDMENT NO. 2 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. THIS AMENDMENT NO. 2 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this ?Amendment?), dated as of January , 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the ?Company? or the ?Borrower?), and the undersigned holders (each, a ?Holder? and, collectively, the ?Holders?). The Company and the
January 14, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers fpmi8kjan82016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2016 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (
January 7, 2016	424B3	FLUOROPHARMA MEDICAL, INC. 31,427,210 shares of Common Stock fpmi424b3jan2016.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-193520 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 31,427,210 shares of Common Stock This prospectus relates to the resale, from time to time, of up to 31,427,210 shares of our common stock, par value $.001 per share (the ?Common Stock?), being offered by the selling stockholders identified in this prospectus. The shares of Commo
December 31, 2015	POS AM	As filed with the Securities and Exchange Commission on December 31, 2015 As filed with the Securities and Exchange Commission on December 31, 2015 Registration No.
December 29, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits fpmi8kdec282015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-15138
December 29, 2015	EX-99.1	FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer - Company to Host Investor Conference Call on January 6th - ex99-1.htm Exhibit 99.1 FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer - Company to Host Investor Conference Call on January 6th - Montclair, NJ - December 29, 2015 - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of
December 9, 2015	LETTER	LETTER Mail Stop 4720 December 9, 2015 Via E-mail Thomas H. Tulip, Ph.D. President Fluoropharma Medical, Inc. 8 Hillside Avenue, Suite 108 Montclair, NJ 07042 Re: Fluoropharma Medical, Inc. Registration Statement on Form S-1 Filed November 24, 2015 File No. 333-208196 Dear Dr. Tulip: This is to advise you that we have not reviewed and will not review your registration statement. We urge all persons who a
November 24, 2015	S-1	As filed with the Securities and Exchange Commission on November 24, 2015 S-1 1 s1fpminov2015.htm FORM S-1 As filed with the Securities and Exchange Commission on November 24, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FLUOROPHARMA MEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 2835 20-8325616 (State or jurisdiction of (Pr
November 24, 2015	8-K	Entry into a Material Definitive Agreement fpmi8knov182015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-15138
November 16, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 fpmi10qsep302015.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2015 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 3
November 13, 2015	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers fpmi8kanov62015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-1513
November 12, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers fpmi8knov62015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381
October 30, 2015	424B3	FLUOROPHARMA MEDICAL, INC. 31,427,210 shares of Common Stock fpmi424b3oct302015.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-193520 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 31,427,210 shares of Common Stock This prospectus relates to the resale, from time to time, of up to 31,427,210 shares of our common stock, par value $.001 per share (the ?Common Stock?), being offered by the selling stockholders identified in this prospectus. The shares of Com
October 22, 2015	POS AM	As filed with the Securities and Exchange Commission on October 22, 2015 As filed with the Securities and Exchange Commission on October 22, 2015 Registration No.
October 16, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits fpmi8koct2015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 2
October 16, 2015	EX-99.1	EX-99.1 ex99-1.htm Exhibit 99.1
October 8, 2015	EX-10.2	AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT ex102.htm Exhibit 10.2 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this ?Amendment?), dated as of October 5, 2015, is made by FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?), and Tamara Rhein (the ?Executive? and, together with the Company, are sometimes referred to individually as ?Party? and collectively as the ?Parties?). RECITALS WHERE
October 8, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits fpmi8koct2015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 5, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (C
October 8, 2015	EX-99.1	Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc. Broad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy ex991.htm Exhibit 99.1 Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc. Broad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy MONTCLAIR, NJ - (Marketwired) - 10/06/15 - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission to
October 8, 2015	EX-10.1	EMPLOYMENT AGREEMENT ex101.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Employment Agreement?) is made and entered into effective as of October 5, 2015 (the ?Effective Date?), by and between FluoroPharma Medical, Inc., a Nevada Corporation with a place of business at 8 Hillside Ave., Suite 108, Montclair NJ 07042 (the ?Company?) and Thomas H. Tulip (the ?Employee?). WHEREAS, the Company desire
October 2, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant fpmi8ksep292015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-1513
August 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2015 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exact
August 12, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commissio
July 22, 2015	8-K	FluoroPharma Medical FORM 8K (Current Report/Significant Event) fpmi8kjuly172015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 16, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (
July 9, 2015	EX-4.1	FLUOROPHARMA MEDICAL, INC. PROMISSORY NOTE ex4-1.htm Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE VIALINK COMPANY SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITI
July 9, 2015	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commission
June 3, 2015	EX-10.2	REGISTRATION RIGHTS AGREEMENT ex10-2.htm REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of May , 2015, by and among FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?), and the purchasers signatory hereto (each, a ?Purchaser? and collectively, the ?Purchasers?). This Agreement is made pursuant to the Note and Warrant Purchase Agreement, dated as of t
June 3, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant fpmi8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 28, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (
June 3, 2015	EX-4.1	CONVERTIBLE PROMISSORY NOTE ex4-1.htm THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE RE
June 3, 2015	EX-4.2	COMMON STOCK PURCHASE WARRANT FLUOROPHARMA MEDICAL, INC. ex4-2.htm NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRAT
June 3, 2015	EX-10.1	NOTE AND WARRANT PURCHASE AGREEMENT ex10-1.htm NOTE AND WARRANT PURCHASE AGREEMENT THIS NOTE AND WARRANT PURCHASE AGREEMENT (this ?Agreement?), is dated as of May , 2015, by and between FluoroPharma Medical, Inc., a Nevada corporation (the ?Company?), and the Purchasers identified on Schedule 1 hereto (the ?Purchasers?). WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon an exemption
May 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2015 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exac
March 31, 2015	EX-10.13	SECOND AMENDMENT TO LEASE EX-10.13 2 leaseam.htm SECOND AMENDMENT TO LEASE AGREEMENT BETWEEN HILSSIDE SQUARE, LLC AND FLUOROPHARMA MEDICAL, INC. DATED AS OF FEBRUARY 2015 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE is made as of the day of February, 2015 by and between HILLSIDE SQUARE LLC, a New Jersey limited liability company (“Lessor”) whose address is c/o The Bravitas Group, 105 Grove Street, Montclair, Ne
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) FluoroPharma Medical, Inc. (Exact name of
January 23, 2015	EX-99.1	EX-99.1 Exhibit 99.1
January 23, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 23, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File Nu
January 16, 2015	424B3	FLUOROPHARMA MEDICAL, INC. 31,640,579 shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-193520 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 31,640,579 shares of Common Stock This prospectus relates to the resale, from time to time, of up to 31,640,579 shares of our common stock, par value $.001 per share (the “Common Stock”), being offered by the selling stockholders identified in this prospectus. The shares of Common Stock offered under
January 13, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2015 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File Nu
January 13, 2015	EX-99.1	EX-99.1 Exhibit 99.1
January 7, 2015	POS AM	FPMI / FluoroPharma Medical, Inc. POS AM - - POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 As filed with the Securities and Exchange Commission on January 7, 2015 Registration No.
December 30, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File N
December 18, 2014	424B3	FLUOROPHARMA MEDICAL, INC. 31,640,579 shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-193520 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 31,640,579 shares of Common Stock This prospectus relates to the resale, from time to time, of up to 31,640,579 shares of our common stock, par value $.001 per share (the “Common Stock”), being offered by the selling stockholders identified in this prospectus. The shares of Common Stock offered under
December 16, 2014	POS AM	FPMI / FluoroPharma Medical, Inc. POS AM - - As filed with the Securities and Exchange Commission on December 16, 2014 Registration No.
December 12, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File N
December 12, 2014	EX-99.1	EX-99.1 Exhibit 99.1
November 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2014 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (
November 14, 2014	NT 10-Q	FPMI / FluoroPharma Medical, Inc. NT 10-Q - - THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
October 21, 2014	CT ORDER	FPMI / FluoroPharma Medical, Inc. CT ORDER - - begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0T(#`@;V)J#3P\+TQI;F5AF4@-3')E9@T,`T)25%3T8-"B`@("`@ M("`@#0HU-B`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``*>@PRH@)$! M),O1@"S&`L4,##<8N!DXONR+(`JE9L/H9DJD!4;>D%$&14!`@P`/9@&7!E+U!A9V4^/@UE;F1O8FH-#<@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I<&4O3V)J4W1M/CYS M=')E86T-"FC>U%7=:]LP$/]7]+@]%'U8LFPHA29;6&$KHPGKH/3!2TQB2.QB MNVS][W=WMF3%3=(M+V,/%TOWI=^=3K\8
August 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2014 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exact
July 25, 2014	EX-10.1	NOTE PURCHASE AGREEMENT Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is dated as of July 22, 2014, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the Purchasers identified on Schedule 1 hereto (the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon an exemption from securities re
July 25, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 22, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commission
July 25, 2014	EX-4.1	PROMISSORY NOTE Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
July 1, 2014	EX-10.2	CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*****]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES A Exhibit 10.2 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*****]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. The General Hospital Corporation LICENSE AGREEMENT Agreement Number: A220396 Invention Record Number(s): 02155 Th
July 1, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commission
July 1, 2014	EX-10.1	CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*****]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES A Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*****]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. The General Hospital Corporation LICENSE AGREEMENT Agreement Number: A220395 Invention Record Number(s): 02390 Th
May 16, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commission
May 16, 2014	EX-99.1	EX-99.1 Exhibit 99.1
May 15, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2014 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exac
March 25, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) FluoroPharma Medical, Inc. (Exact name of
March 25, 2014	EX-10.14	INDEPENDENT CONSULTING AGREEMENT EX-10.14 2 ex10-14.htm Exhibit 10.14 INDEPENDENT CONSULTING AGREEMENT This Independent Consulting Agreement (“Agreement”), effective as of March 6, 2014 (“Effective Date”) is entered into by and between FLUOROPHARMA MEDICAL, INC., a Nevada corporation (herein referred to as the “Company”), and THE DEL MAR CONSULTING GROUP, INC., a California corporation and ALEX PARTNERS, LLC, a Washington State L
March 14, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commissio
March 14, 2014	EX-99.1	FluoroPharma Announces Appointment of Andrew H. Sassine to the Board of Directors Exhibit 99.1 FluoroPharma Announces Appointment of Andrew H. Sassine to the Board of Directors MONTCLAIR, NJ - (Marketwired) – 03/11/14 - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today a
February 18, 2014	CT ORDER	- begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0S(#`@;V)J#3P\+TQI;F5AF4@-38O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R!!(,4X`$XPT@P1(,)-A!Q"=.!B9&AET@609&=.(XXP``$&`+1-!N,- M"F5N9'-TEWI],OFA%&-"?<$BV(T&XC"5="$ZT(3YSE@=Y, MIY.LR5=$6>=\]WAY2:^;95ZVA#.1T&GV]"DOUIN6)(F@'+.="&9H;-MMFZ( M5'16E>UD4OUZN-#:HHT(QA@F>$3K+-L5VY=WBV7-^0VTGNJEU6OD?;;;;+ M5J<`?5?YQ>3:KOZLD#[O*WS=KFAMU6]R[:HNN\0&<;H
February 14, 2014	424B3	32,163,558 shares of Common Stock FLUOROPHARMA MEDICAL, INC. Filed Pursuant to Rule 424(b)(3) Registration No. 333-193520 Prospectus Supplement No. 1 (To prospectus dated February 12, 2014) 32,163,558 shares of Common Stock FLUOROPHARMA MEDICAL, INC. This prospectus supplement, dated February 14, 2014, supplements the prospectus, dated February 12, 2014, of FluoroPharma Medical, Inc., relating to the resale by the selling stockholders of up to 32,163,558 sh
February 12, 2014	424B3	FLUOROPHARMA MEDICAL, INC. 32,163,558 shares of Common Stock ______________________ This prospectus relates to the resale, from time to time, of up to 32,163,558 shares of our common stock, par value $.001 per share (the “Common Stock”), being offere Filed pursuant to Rule 424(b)(3) Registration No. 333-193520 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 32,163,558 shares of Common Stock This prospectus relates to the resale, from time to time, of up to 32,163,558 shares of our common stock, par value $.001 per share (the “Common Stock”), being offered by the selling stockholders identified in this prospectus. The shares of Common Stock offered under
February 11, 2014	CORRESP	- February 11, 2014 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: FluoroPharma Medical, Inc. Pre-Effective Amendment No. 1 to Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-193520 Ladies and Gentlemen: FluoroPharma Medical, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement
February 11, 2014	S-1/A	- FORM S-1/A As filed with the Securities and Exchange Commission on February 11, 2014 Registration No.
February 6, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2014 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commiss
February 6, 2014	EX-99.1	Data Presented from FluoroPharma’s Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Acute and Chronic Forms of Coronary Artery Disease (CAD) Exhibit 99.1 Data Presented from FluoroPharma’s Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Acute and Chronic Forms of Coronary Artery Disease (CAD) Data presented at 2014 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Winter Meeting could be an important development for patients with coronary disease and potential compelling new direction for PET cardiac imaging
January 30, 2014	LETTER	LETTER January 30, 2014 Via E-Mail Tamara Rhein Chief Financial Officer FluoroPharma Medical, Inc.
January 23, 2014	EX-10.1	CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “**” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EX Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “**” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT MGH Agreement Number: A202234 MGH Case Numbers: 968, 1261, 2390 and 2155 THIS LICENSE AGRE
January 23, 2014	S-1	Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on January 23, 2014 Registration No.
January 13, 2014	POS AM	- POST-EFFECTIVE AMENDMENT NO. 2 TO REGISTRATION STATEMENT ON FORM S-1 As filed with the Securities and Exchange Commission on January 13, 2014 Registration No.
January 13, 2014	CORRESP	- FluoroPharma Medical, Inc. 8 Hillside Avenue, Suite 207 Montclair, New Jersey 07042 VIA EDGAR January 13, 2014 Jeffrey P. Riedler Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Fluoropharma Medical, Inc. Post-Effective Amendment No. 2 to Registration Statement on Form S-1 Filed January 3, 2014 File No. 333-185643 Dear Mr. Riedler: On behalf of Fluoropharma Medica
January 13, 2014	CORRESP	- January 13, 2014 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: FluoroPharma Medical, Inc. Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-185643 Ladies and Gentlemen: FluoroPharma Medical, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement
January 10, 2014	LETTER	LETTER January 10, 2014 Via E-mail Johan M. (Thijs) Spoor Chief Executive Officer Fluoropharma Medical, Inc. 8 Hillside Avenue, Suite 207 Montclair, NJ 07042 Re: Fluoropharma Medical, Inc. Post-Effective Amendment No. 2 to Registration Statement on Form S-1 Filed January 3, 2014 File No. 333-185643 Dear Mr. Spoor: We have limited our review of your registration statement to the issue we have addressed in
January 10, 2014	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2014 Commission File Number: 333-147193 FluoroPharma Medical, Inc.
January 7, 2014	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 31, 2013, between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi
January 7, 2014	EX-4.1	COMMON STOCK PURCHASE WARRANT FLUOROPHARMA MEDICAL, INC. Warrant Shares: [_______] Initial Exercise Date: December 31, 2013 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA
January 7, 2014	EX-10.2	REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 31, 2013, among FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, d
January 7, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2013 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File N
January 3, 2014	POS AM	- POST-EFFECTIVE AMENDMENT NO. 2 TO REGISTRATION STATEMENT ON FORM S-1 As filed with the Securities and Exchange Commission on January 3, 2014 Registration No.
December 5, 2013	EX-99.1	-1- Exhibit 99.1 -1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- -39- -40- -41- -42- -43- -44- -45- -46- -47- -48-
December 5, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 5, 2013 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commiss
November 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 fpmi10qsept302013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2013 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193
October 29, 2013	EX-99.1	October 28, 2013 Exhibit 99.1 October 28, 2013 FluoroPharma Medical, Inc. Names GE Healthcare Veteran, Edward L. Lyons, Jr. to Newly Created Position of Vice President, Marketing Broad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy and Strengthens Goal for Commercialization in 2016 MONTCLAIR, NJ - (Marketwired) - 10/28/13 - FluoroPharma Medical, Inc. (OTCQB:FPMI),
October 29, 2013	8-K	Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2013 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 20-8325616 (Commiss
September 19, 2013	EX-4.1	RESTATED CERTIFICATE OF DESIGNATION OF THE RELATIVE RIGHTS AND PREFERENCES OF THE SERIES B PREFERRED STOCK OF FLUOROPHARMA MEDICAL, INC. Exhibit 4.1 RESTATED CERTIFICATE OF DESIGNATION OF THE RELATIVE RIGHTS AND PREFERENCES OF THE SERIES B PREFERRED STOCK OF FLUOROPHARMA MEDICAL, INC. The undersigned, Chief Executive Officer of FluoroPharma Medical, Inc., a Nevada corporation (the “Corporation” or the “Company”), DOES HEREBY CERTIFY that pursuant to the authority conferred upon the Board of Directors by the Articles of Incorporatio
September 19, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FLUOROPHARMA FORM 8-K SEPT 19 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 18, 2013 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File
September 19, 2013	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 18, 2013 by and among FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each of the Purchasers whose names are set forth on the signature pages hereto (individually, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the Pur
September 19, 2013	EX-10.2	REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 18, 2013, among FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement,
September 19, 2013	EX-4.2	COMMON STOCK PURCHASE WARRANT FLUOROPHARMA MEDICAL, INC. Warrant Shares: [_______] Initial Exercise Date: September 18, 2013 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA
August 19, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2013 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exact
August 14, 2013	NT 10-Q	- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
July 31, 2013	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2013 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
July 31, 2013	EX-99.1	FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication Exhibit 99.1 FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication Emphasis on Clear Business and Financial Model, Experienced Management Team, Significant Intellectual Property, Progress in Pipeline With Billion Dollar Market Potential MONTCLAIR, NJ - (Marketwired) - 07/29/13 - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel
June 26, 2013	EX-99.2	FluoroPharma Medical Announces Internal Review of Currently Acquired Imaging Data From Phase II Study for CardioPET(TM) (FCPHA) Exhibit 99.2 FluoroPharma Medical Announces Internal Review of Currently Acquired Imaging Data From Phase II Study for CardioPET(TM) (FCPHA) Images Continue to Be Impressive, Providing High Resolution in the Heart and Clear Image Quality for Early and Late Scans MONTCLAIR, NJ - (Marketwired) - 06/20/13 - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel d
June 26, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2013 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
June 26, 2013	EX-99.1	NOTE PURCHASE AGREEMENT Exhibit 99.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is dated as of June , 2013, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the Purchasers identified on Schedule 1 hereto (the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon an exemption from securities regi
May 15, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2013 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exac
May 7, 2013	EX-99.1	-48- Exhibit 99.1 -48-
May 7, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2013 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emplo
April 15, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2013 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
April 15, 2013	EX-10.1	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS IS AMENDMENT NO. 1 TO THE EMPLOYMENT AGREEMENT, entered into as of April 9, 2013, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and Johan M. (Thijs) Spoor (the “Executive”) (the “Agreement”). WHEREAS, Company previously entered into an employment agreement with Executive dated as of July 30, 2012 (the “Employmen
April 15, 2013	EX-99.1	FluoroPharma Announces Appointment of Dr. Joseph A. Pierro to the Board of Directors Exhibit 99.1 FluoroPharma Announces Appointment of Dr. Joseph A. Pierro to the Board of Directors MONTCLAIR, NJ-(Marketwired - April 15, 2013) -FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleas
March 28, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) FluoroPharma Medical, Inc. (Exact name of
March 6, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2013 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
March 6, 2013	EX-99.1	EX-99.1 Exhibit 99.1
March 6, 2013	EX-99.2	FluoroPharma Medical Announces Initial Data From Phase II Study for CardioPET(TM) (FCPHA) Images Show High Resolution in the Heart and Provides Extremely Clear Image Quality, Bolstering Confidence in CardioPET Exhibit 99.2 FluoroPharma Medical Announces Initial Data From Phase II Study for CardioPET(TM) (FCPHA) Images Show High Resolution in the Heart and Provides Extremely Clear Image Quality, Bolstering Confidence in CardioPET MONTCLAIR, NJ-(Marketwire - February 28, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize p
January 10, 2013	424B3	PROSPECTUS FLUOROPHARMA MEDICAL, INC. 3,820,150 shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-185643 PROSPECTUS FLUOROPHARMA MEDICAL, INC. 3,820,150 shares of Common Stock This prospectus relates to the public offering of up to 3,820,150 shares of common stock, par value $0.001 per share (the “Common Stock”), of FluoroPharma Medical, Inc., by the selling stockholders. The total amount of shares consists of 1,819,119 shares of Common Sto
January 4, 2013	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO S-1 As filed with the Securities and Exchange Commission on January 4, 2013 Registration No.
January 2, 2013	8-K	Regulation FD Disclosure - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 2, 2013 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS E
January 2, 2013	EX-99.1	EX-99.1 Exhibit 99.1
December 31, 2012	CORRESP	- FluoroPharma Medical, Inc. 8 Hillside Avenue, Suite 207 Montclair, New Jersey 07042 VIA EDGAR December 31, 2012 Jeffrey P. Riedler Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Fluoropharma Medical, Inc. Registration Statement on Form S-1 Filed December 21, 2012 File No. 333-185643 Dear Mr. Riedler: On behalf of Fluoropharma Medical, Inc., a Nevada corporation (
December 31, 2012	S-1/A	- AMENDMENT NO. 1 TO FORM S-1 As filed with the Securities and Exchange Commission on December 31, 2012 Registration No.
December 31, 2012	LETTER	LETTER December 28, 2012 Via E-mail Mr. Johan M. (Thijs) Spoor Chief Executive Officer Fluoropharma Medical, Inc. 8 Hillside Avenue, Suite 207 Montclair, NJ 07042 Re: Fluoropharma Medical, Inc. Registration Statement on Form S-1 Filed December 21, 2012 File No. 333-185643 Dear Mr. Spoor: We have limited our review of your registration statement to the issue we have addressed in our comment. In our commen
December 31, 2012	CORRESP	- December 31, 2012 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: FluoroPharma Medical, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-185643 Ladies and Gentlemen: FluoroPharma Medical, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 2:00 p.m. on De
December 21, 2012	S-1	Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on December 21, 2012 Registration No.
December 21, 2012	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on December 21, 2012 Registration No.
December 21, 2012	EX-4.1	EX-4.1 Exhibit 4.1
November 21, 2012	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2012 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-151381 (Commission File N
November 21, 2012	EX-4.1	COMMON STOCK PURCHASE WARRANT FLUOROPHARMA MEDICAL, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA
November 21, 2012	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 19, 2012, between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi
November 21, 2012	EX-10.2	REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 19, 2012, among FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, d
November 21, 2012	EX-99.1	FluoroPharma Medical, Inc. Announces $1.5M Equity Financing Exhibit 99.1 FluoroPharma Medical, Inc. Announces $1.5M Equity Financing MONTCLAIR, NJ, November 20, 2012 - FluoroPharma Medical, Inc. (OTCBB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that it completed a p
November 14, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2012 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (
September 11, 2012	EX-99.1	-1- Exhibit 99.1 -1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34-
September 11, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IR
August 22, 2012	EX-99	FluoroPharma Announces the Promotion of Tamara Rhein to CFO Exhibit 99.1 FluoroPharma Announces the Promotion of Tamara Rhein to CFO Download PDF MONTCLAIR, N.J., Aug. 22, 2012 (GLOBE NEWSWIRE) - FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased
August 22, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS E
August 22, 2012	EX-16	August 17, 2012 Exhibit 16.1 August 17, 2012 Securities and Exchange Commission Office of the Chief Accountant 100 F Street NE Washington DC 20549 Ladies and Gentlemen: We have read Item 4.01 of the Form 8-K dated August 17, 2012 of FluoroPharma Medical Inc. and are in agreement with the statements insofar as they relate to our firm. We have no basis to agree or disagree with the other statements of the registran
August 22, 2012	EX-10	EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 22nd day of August 2012, by and between FluoroPharma Medical, Inc., a Delaware corporation with offices at 8 Hillside Avenue, Suite 207, Montclair, NJ 07042 (the “Company”), and Tamara Rhein, an individual residing at (“Executive”). W I T N E S S E T H: WHEREAS, the Executive desires t
August 22, 2012	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS E
August 1, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
August 1, 2012	EX-10.1	EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Employment Agreement”) is made and entered into effective as of July 30, 2012, (the “Effective Date”), by and between FluoroPharma Medical, Inc., a Nevada Corporation with a place of business at 8 Hillside Av., Suite 207, Montclair NJ 07042 (the “Company”) and Johan M. (Thijs) Spoor (the “Employee”). WHEREAS, the Employee entered in
August 1, 2012	EX-99.1	FluoroPharma Announces Milestone for BFPET Exhibit 99.1 FluoroPharma Announces Milestone for BFPET Initial Images Show Positive Results for BFPET in Patients With Coronary Artery Disease MONTCLAIR, N.J., July 26, 2012 (GLOBE NEWSWIRE) - FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and asses
July 27, 2012	POS AM	- AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 27, 2012 REGISTRATION NO.
July 27, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2012 [ ] Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exact
June 18, 2012	EX-99.2	-1- Exhibit 99.2 FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication Shaping the Future of Molecular PET Imaging to Enable Earliest Possible Diagnosis of Disease - Even Before Symptoms Appear MONTCLAIR, N.J., June 18, 2012 (GLOBE NEWSWIRE) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of breakthrough molecular imaging products that utilize
June 18, 2012	EX-99.1	EX-99.1 Exhibit 99.1
June 18, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
June 15, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 15, 2012	EX-99	Thijs Spoor Appointed Chairman of the Board of FluoroPharma Medical, Inc. Exhibit 99.1 Thijs Spoor Appointed Chairman of the Board of FluoroPharma Medical, Inc. Montclair June 15, 2012 (GLOBE NEWSWIRE) - FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to an
June 15, 2012	EX-17	David Elmaleh <__________________> Exhibit 17.1 From: David Elmaleh <>Date: June 12, 2012 2:20:40 AM EDTTo: Thijs Spoor <>, "" <>, Walter Witoshkin <>, Peter Conti <>Subject: resignation Dear Board, Due to irreconcilable differences with management I can no longer be involved with FluoroPharma Medical Inc. Effective today, I am resigning as company Chairman and director and separate myself from all company activities. My resignatio
May 15, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exact na
April 16, 2012	EX-99.1	EX-99.1
April 16, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Em
April 13, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
March 16, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) o ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) FluoroPharma Medical, Inc. (Exact name of regi
March 16, 2012	EX-14	ETHICAL GUIDELINES ADOPTED BY THE BOARD OF DIRECTORS FluoroPharma Medical On July 22, 2011 Exhibit 14 ETHICAL GUIDELINES ADOPTED BY THE BOARD OF DIRECTORS OF FluoroPharma Medical On July 22, 2011 INTRODUCTION These Ethical Guidelines will serve as FluoroPharma Corporation’s Code of Ethics (“Guidelines”) and as such they cover a wide spectrum of business practices and procedures.
March 7, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FLUOROPHARMA 8-K MARCH 7, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2012 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS Emp
March 7, 2012	EX-99.1	FluoroPharma Medical Announces Phase II Study for CardioPET Company Advances First in Class Diagnostic Agent for the Detection and Assessment of Acute and Chronic Forms of Coronary Disease That Affects Millions of Patients Worldwide EX 99.1 FluoroPharma Medical Announces Phase II Study for CardioPET Company Advances First in Class Diagnostic Agent for the Detection and Assessment of Acute and Chronic Forms of Coronary Disease That Affects Millions of Patients Worldwide BOSTON, March 1, 2012 (GLOBE NEWSWIRE) - FluoroPharma Medical, Inc. (OTCBB:FPMI.OB - News), a company specializing in the development of breakthrough diagnosti
January 5, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2011 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS
December 19, 2011	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2011 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS
December 19, 2011	424B3	PROSPECTUS SUPPLEMENT NO. 1 Prospectus Supplement No. 1 dated December 19, 2011 to Prospectus filed on November 3, 2011 and Registration Statement on Form S-1 declared effective on November 2, 2011 (Registration No. 333-175647) FLUOROPHARMA MEDICAL, Filed Pursuant to Rule 424(b)(3) under the Securities Act of 1933, as amended (File No.
November 30, 2011	EX-99.2	FluoroPharma Expands Patent Position in the U.S. for Detecting Alzheimer’s Disease and in China for Imaging Blood Flow in the Heart EXHIBIT 99.2 FluoroPharma Expands Patent Position in the U.S. for Detecting Alzheimer’s Disease and in China for Imaging Blood Flow in the Heart BOSTON, MA Nov. 29, 2011 /Marketwire/ - FluoroPharma Medical, Inc. (OTCBB: FPMI) today announces that composition of matter patents covering AZPET, the Company’s Alzheimer’s Disease agent, have been issued by the U.S. patent office expiring in 2028. Fluor
November 30, 2011	EX-99.1	EX-99.1 EX-99.1 2 ex99-1.htm POWERPOINT PRESENTATION EXHIBIT 99.1
November 30, 2011	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2011 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS
November 22, 2011	LETTER	LETTER November 22, 2011 Via Facsimile Johan M. (Thijs) Spoor Chief Executive Officer, President and Chief Financial Officer FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FluoroPharma Medical, Inc. Item 4.01 Form 8-K Filed November 7, 2011 File No. 333-147193 Dear Mr. Spoor: We have completed our review of your filing. We remind you that our comments or changes to disclo
November 21, 2011	8-K/A	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K /A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2011 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commissio
November 21, 2011	CORRESP	- FLUOROPHARMA MEDICAL, INC. 500 Boylston Street, Suite 1600 Boston, MA 02116 November 21, 2011 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-3561 Attn: Joel Parker, Accounting Branch Chief Vanessa Robertson, Staff Accountant Re: FluoroPharma Medical, Inc. Item 4.01 Form 8-K Filed November 7, 2011 File No. 333-147193
November 17, 2011	LETTER	LETTER November 17, 2011 Via Facsimile Johan M. (Thijs) Spoor Chief Executive Officer, President and Chief Financial Officer FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FluoroPharma Medical, Inc. Item 4.01 Form 8-K Filed November 7, 2011 File No. 333-147193 Dear Mr. Spoor: We have reviewed your filing and have the following comments. Please respond to this letter withi
November 14, 2011	EX-10.3	FLUOROPHARMA, INC. 222 Berkley Street, Suite 1040 Boston, Massachusetts 02116 EX-10.3 4 ex10-3.htm EMPLOYMENT AGREEMENT BETWEEN JOHAN "THIJS" SPOOR AND FLUOROPHARMA, INC. EXHIBIT 10.3 FLUOROPHARMA, INC. 222 Berkley Street, Suite 1040 Boston, Massachusetts 02116 As of January 1, 2011 Johan Spoor c/o FluoroPharma, Inc. 222 Berkley Street, Suite 1040 Boston, Massachusetts 02116 Dear Thijs: This letter agreement summarizes the terms and conditions of your employment with Fluoro
November 14, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exac
November 14, 2011	EX-10.1	OFFICE USE AGREEMENT EX-10.1 2 ex10-1.htm OFFICE USE AGREEMENT EXHIBIT 10.1 OFFICE USE AGREEMENT This Agreement is by and between PureTech Ventures, LLC ("PureTech") and FluoroPharma Medical, Inc. ("FluoroPharma") as of June 22, 2011 the ("Effective Date"). WHEREAS, PureTech desires to provide, and FluoroPharma desires to use, certain of office space and telecommunications equipment located at Suite 1600 (the "Office
November 14, 2011	EX-10.2	LEASE AGREEMENT BY AND BETWEEN HILLSIDE SQUARE LLC, LESSOR, FLOUROPHARMA, INC., LESSEE LEASED PREMISES: HILLSIDE SQUARE 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR, NEW JERSEY 07042 EX-10.2 3 ex10-2.htm LEASE AGREEMENT BETWEEN HILLSIDE SQUARE LLC AND FLUOROPHARMA, INC. EXHIBIT 10.2 LEASE AGREEMENT BY AND BETWEEN HILLSIDE SQUARE LLC, LESSOR, -and- FLOUROPHARMA, INC., LESSEE LEASED PREMISES: HILLSIDE SQUARE 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR, NEW JERSEY 07042 THIS LEASE AGREEMENT is made this 8th day of September, 2011 by and between HILLSIDE SQUARE LLC, a New Jersey limited
November 7, 2011	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2011 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS
November 3, 2011	424B3	FLUOROPHARMA MEDICAL, INC. PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No: 333-175647 FLUOROPHARMA MEDICAL, INC.
October 31, 2011	CORRESP	- FLUOROPHARMA MEDICAL, INC. 500 Boylston Street, Suite 1600 Boston, MA 02116 October 31, 2011 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Pamela Long Edward. M. Kelly Re: FluoroPharma Medical, Inc. Registration Statement on Form S-1 File No. 333-175647 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regu
October 27, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 27 , 2011 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 27 , 2011 REGISTRATION NO.
October 24, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 24 , 2011 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 24 , 2011 REGISTRATION NO.
October 24, 2011	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-4631 DIVISION OF CORPORATION FINANCE October 24, 2011 Via U.S. Mail Mr. Johan M. (Thijs) Spoor Chief Executive Officer FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FluoroPharma Medical, Inc. Pre-effective Amendment 5 to Registration Statement on Form S-1 Filed October 18, 2011 File No. 333-17
October 18, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 18 , 2011 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 18 , 2011 REGISTRATION NO.
October 17, 2011	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-4631 DIVISION OF CORPORATION FINANCE October 17, 2011 Via U.S. Mail Mr. Johan M. (Thijs) Spoor Chief Executive Officer FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FluoroPharma Medical, Inc. Current Report on Form 8-K Filed May 16, 2011 File No. 333-147193 Dear Mr. Spoor: We have completed ou
October 5, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 5 , 2011 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 5 , 2011 REGISTRATION NO.
October 4, 2011	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q /A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q /A (Amendment No. 1) (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 333-147193 FluoroPharma Med
October 3, 2011	CORRESP	- FLUOROPHARMA MEDICAL, INC. 500 Boylston Street, Suite 1600 Boston, MA 02116 September 30, 2011 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Pamela A. Long, Esq. Edward M. Kelly, Esq. Re: FluoroPharma Medical, Inc. Pre-effective Amendment No. 2 to Registration Statement on Form S-1 Filed September 8, 2011
October 3, 2011	CORRESP	- FLUOROPHARMA MEDICAL, INC. 500 Boylston Street, Suite1600 Boston, MA 02116 October 3, 2011 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-3561 Attention: Jay E. Ingram, Esq. Edward M. Kelly, Esq. Ernest M. Greene Nudrat S. Salik Re: FluoroPharma Medical, Inc. Current Report on Form 8-K Filed May 16, 2011 File No. 333
October 3, 2011	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2011 FluoroPharma Medical, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 333-151381 20-8325616 (State or Other Jurisdiction (Commission File Number) (IRS
October 3, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 3 , 2011 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 3 , 2011 REGISTRATION NO.
September 26, 2011	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-4631 DIVISION OF CORPORATION FINANCE September 26, 2011 Via U.S. Mail Dr. David R. Elmaleh Chairman FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FluoroPharma Medical, Inc. Pre-effective Amendment No. 2 to Registration Statement on Form S-1 Filed September 8, 2011 File No. 333-175647 Dear Dr.
September 23, 2011	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-4631 DIVISION OF CORPORATION FINANCE September 23, 2011 Via U.S. Mail Johan M. (Thijs) Spoor Chief Executive Officer FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FlouroPharma Medical, Inc. Current Report on Form 8-K dated February 14, 2011 Filed May 16, 2011 File No. 333-147193 Form 10-Q for
September 9, 2011	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Mark One) o ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 333-147193 (Commission file number) FluoroPharma Medical, Inc. (Exact name of r
September 8, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 7, 2011 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 7, 2011 REGISTRATION NO.
September 8, 2011	CORRESP	- FLUOROPHARMA MEDICAL, INC. 500 Boylston Street, Suite1600 Boston, MA 02116 September 8, 2011 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-3561 Attention: Re: Jay E. Ingram, Esq. Edward M. Kelly, Esq. Ernest M. Greene Nudrat S. Salik FluoroPharma Medical, Inc. Amendment 2 to Current Report on Form 8-K dated May 16,
September 7, 2011	CORRESP	- FLUOROPHARMA MEDICAL, INC. 500 Boylston Street, Suite 1600 Boston, MA 02116 September 7, 2011 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Re: Pamela A. Long, Esq. Edward M. Kelly, Esq. FluoroPharma Medical, Inc. Registration Statement on Form S-1 Filed July 18, 2011 File No. 333-175647 Dear Ms. Long: We
September 7, 2011	S-1/A	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 7, 2011 S-1/A 1 flphs1a-july2011.htm S-1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 7, 2011 REGISTRATION NO. 333-175647 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FluoroPharma Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 2835 20-8325616 (State or jurisdictio
August 16, 2011	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-4631 DIVISION OF CORPORATION FINANCE August 16, 2011 Via U.S. Mail Johan M. (Thijs) Spoor Chief Executive Officer FluoroPharma Medical, Inc. 500 Boylston Street, Suite 1600 Boston, MA 02116 Re: FlouroPharma Medical, Inc. Amendment 2 to Current Report on Form 8-K dated May 16, 2011 Filed August 4, 2011 Annual Report on Form 10-
August 15, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 333-147193 FluoroPharma Medical, Inc. (Exact nam

FPMI / FluoroPharma Medical, Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

Podstawowe statystyki

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?